Are you over 18 and want to see adult content?
More Annotations
A complete backup of mclellanmarketing.com
Are you over 18 and want to see adult content?
A complete backup of plasticsurgery4cyprus.com
Are you over 18 and want to see adult content?
A complete backup of goodmorningimagesforlover.com
Are you over 18 and want to see adult content?
A complete backup of dompetdhuafa.org
Are you over 18 and want to see adult content?
A complete backup of freshstorebuilder.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://countyofamherst.com
Are you over 18 and want to see adult content?
A complete backup of https://nuagedesigns.com
Are you over 18 and want to see adult content?
A complete backup of https://jettloans.com
Are you over 18 and want to see adult content?
A complete backup of https://wxwidgets.org
Are you over 18 and want to see adult content?
A complete backup of https://best-tanning.com
Are you over 18 and want to see adult content?
A complete backup of https://garant-1service.ru
Are you over 18 and want to see adult content?
A complete backup of https://doxycyclinetab.com
Are you over 18 and want to see adult content?
A complete backup of https://vanillamagazine.it
Are you over 18 and want to see adult content?
A complete backup of https://opengovus.com
Are you over 18 and want to see adult content?
A complete backup of https://hidrb.com
Are you over 18 and want to see adult content?
A complete backup of https://eckhauslatta.com
Are you over 18 and want to see adult content?
A complete backup of https://ralfvanveen.com
Are you over 18 and want to see adult content?
Text
and biological
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. MECHANISM OF ACTION OF A NOVEL AGONIST TNFR2-ANTIBODY THAT TNFR2 is a member of the TNF receptor superfamily that is upregulated upon T cell activation and is highly expressed by tumor-infiltrating effector and regulatory T cells (T MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. MERRIMACK PHARMACEUTICALSPRESS RELEASESEVENTS & PRESENTATIONSOVERVIEWBOARD OF DIRECTORSCOMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. INVESTORS | MERRIMACK PHARMACEUTICALS Investors. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathwaysand biological
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. MECHANISM OF ACTION OF A NOVEL AGONIST TNFR2-ANTIBODY THAT TNFR2 is a member of the TNF receptor superfamily that is upregulated upon T cell activation and is highly expressed by tumor-infiltrating effector and regulatory T cells (T MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC.OUR SCIENCE
Our research suggests that two pathways — HER3 and IGF-1 — cooperate to drive a master control of cancer cells’ growth. Merrimack has uniquely discovered that the blockade of these two pathways should be more effective if one drug blocked both receptors rather than two drugs acting separately. SOLUTION. MM-141 is an engineered monoclonal EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com CONTACT IR | MERRIMACK PHARMACEUTICALS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.comSEC FILINGS
SEC Filings | Merrimack Pharmaceuticals. SEC Filings. Type. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003. - Any -. CORPORATE GOVERNANCE Corporate Governance. Merrimack’s board of directors sets high standards for the Company's employees, officers and directors. Implicit in this philosophy and Merrimack’s responsibility to patients, is the importance of sound corporate governance. To fulfill its responsibilities, the board follows the procedures and standardsthat are set
MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK RECEIVES ORPHAN DRUG DESIGNATION FOR MM-121 FOR CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer.MM-121 (seribantumab) is a fully human monoclonal antibody designed to MERRIMACK DISCONTINUES DEVELOPMENT OF MM-310 CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. This decision was the result of a comprehensive review of available safety data from itsPhase
RSS | MERRIMACK PHARMACEUTICALS An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook. Some web browsers, such as Firefox and Safari RSS, have RSS readers built in. There are also online aggregators, websites such as My Yahoo or Bloglines that allow you to customize them by adding RSS feeds. MERRIMACK PHARMACEUTICALSPRESS RELEASESEVENTS & PRESENTATIONSOVERVIEWBOARD OF DIRECTORSCOMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. INVESTORS | MERRIMACK PHARMACEUTICALS Investors. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathwaysand biological
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. MECHANISM OF ACTION OF A NOVEL AGONIST TNFR2-ANTIBODY THAT TNFR2 is a member of the TNF receptor superfamily that is upregulated upon T cell activation and is highly expressed by tumor-infiltrating effector and regulatory T cells (T MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. MERRIMACK PHARMACEUTICALSPRESS RELEASESEVENTS & PRESENTATIONSOVERVIEWBOARD OF DIRECTORSCOMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. INVESTORS | MERRIMACK PHARMACEUTICALS Investors. Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathwaysand biological
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. MECHANISM OF ACTION OF A NOVEL AGONIST TNFR2-ANTIBODY THAT TNFR2 is a member of the TNF receptor superfamily that is upregulated upon T cell activation and is highly expressed by tumor-infiltrating effector and regulatory T cells (T MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC.OUR SCIENCE
Our research suggests that two pathways — HER3 and IGF-1 — cooperate to drive a master control of cancer cells’ growth. Merrimack has uniquely discovered that the blockade of these two pathways should be more effective if one drug blocked both receptors rather than two drugs acting separately. SOLUTION. MM-141 is an engineered monoclonal EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com CONTACT IR | MERRIMACK PHARMACEUTICALS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.comSEC FILINGS
SEC Filings | Merrimack Pharmaceuticals. SEC Filings. Type. 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements. Filing year. - Any - 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003. - Any -. CORPORATE GOVERNANCE Corporate Governance. Merrimack’s board of directors sets high standards for the Company's employees, officers and directors. Implicit in this philosophy and Merrimack’s responsibility to patients, is the importance of sound corporate governance. To fulfill its responsibilities, the board follows the procedures and standardsthat are set
MERRIMACK PHARMACEUTICALS ISSUES LETTER TO SHAREHOLDERS CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 26, 2019-- The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held MERRIMACK RECEIVES ORPHAN DRUG DESIGNATION FOR MM-121 FOR CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer.MM-121 (seribantumab) is a fully human monoclonal antibody designed to MERRIMACK DISCONTINUES DEVELOPMENT OF MM-310 CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. This decision was the result of a comprehensive review of available safety data from itsPhase
RSS | MERRIMACK PHARMACEUTICALS An RSS aggregator can be a stand-alone application, or a plug-in for another program you already use, such as Microsoft Outlook. Some web browsers, such as Firefox and Safari RSS, have RSS readers built in. There are also online aggregators, websites such as My Yahoo or Bloglines that allow you to customize them by adding RSS feeds. MERRIMACK PHARMACEUTICALSPRESS RELEASESEVENTS & PRESENTATIONSOVERVIEWBOARD OF DIRECTORSCOMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. INVESTORS | MERRIMACK PHARMACEUTICALS The Investor Relations website contains information about Merrimack Pharmaceuticals's business for stockholders, potential investors, andfinancial analysts.
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. CORPORATE GOVERNANCE Merrimack’s board of directors sets high standards for the Company's employees, officers and directors. Implicit in this philosophy and Merrimack’s responsibility to patients, is the importance of sound corporate governance.SEC FILINGS
Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. MERRIMACK RECEIVES ORPHAN DRUG DESIGNATION FOR MM-121 FOR CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer.MM-121 (seribantumab) is a fully human monoclonal antibody designed to MERRIMACK PHARMACEUTICALSPRESS RELEASESEVENTS & PRESENTATIONSOVERVIEWBOARD OF DIRECTORSCOMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. (“Ipsen”) in April 2017. INVESTORS | MERRIMACK PHARMACEUTICALS The Investor Relations website contains information about Merrimack Pharmaceuticals's business for stockholders, potential investors, andfinancial analysts.
PARTNERING OPPORTUNITIES TNFR2 AGONIST ANTIBODY PROGRAM Partnering Opportunities TNFR2 Agonist Antibody Program (MM-401) • Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK PHARMACEUTICALS ANNOUNCES COMPLETION OF CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related ENGINEERING AND PRECLINICAL ACTIVITY OF MM-201, A A PASSION FOR OUTTHINKING CANCER. Early attempts at using TNF superfamily members for anticancer therapies, TNF and FAS, led to serious systemic toxicities. CORPORATE GOVERNANCE Merrimack’s board of directors sets high standards for the Company's employees, officers and directors. Implicit in this philosophy and Merrimack’s responsibility to patients, is the importance of sound corporate governance.SEC FILINGS
Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MERRIMACK DISCONTINUES PHASE 2 SHERLOC STUDY OF MM-121 IN CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. MERRIMACK RECEIVES ORPHAN DRUG DESIGNATION FOR MM-121 FOR CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer.MM-121 (seribantumab) is a fully human monoclonal antibody designed toSTOCK INFORMATION
Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com CONTACT IR | MERRIMACK PHARMACEUTICALS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com EVENTS & PRESENTATIONS Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.comSEC FILINGS
Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.comPRIVACY POLICY
Privacy Policy Overview. Merrimack Pharmaceuticals, Inc. (“Merrimack”) knows that you care how information about you is used and shared, and we appreciate your CORPORATE GOVERNANCE Merrimack’s board of directors sets high standards for the Company's employees, officers and directors. Implicit in this philosophy and Merrimack’s responsibility to patients, is the importance of sound corporate governance. MERRIMACK PHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com MECHANISM OF ACTION OF A NOVEL AGONIST TNFR2-ANTIBODY THAT TNFR2 is a member of the TNF receptor superfamily that is upregulated upon T cell activation and is highly expressed by tumor-infiltrating effector and regulatory T cells (T COMMITTEE COMPOSITION Merrimack Pharmaceuticals, Inc. One Broadway, 14th floor Cambridge, MA 02142 617-720-8606 info@merrimack.com D N I V O L U M A B ( A N T I An anti-human TNFR2 antibody protects against xenogeneic GvHD Epitope of human antibody corresponds with surrogate mouse antibody A PASSION FOR OUTTHINKING CANCER * Merrimack Pharmaceuticals*
* Investors
* Press Releases
* Events & Presentations * Corporate Governance* Overview
* Board of Directors * Committee Composition* SEC Filings
* Stock Information
* Stock Quote & Chart * Historic Stock Lookup * Investment Calculator* Investor FAQs
* Contact IR
*
BACK
* Investors
* Investors
* Press Releases
* Events & Presentations * Corporate Governance*
BACK
* Corporate Governance * Corporate Governance* Overview
* Board of Directors * Committee Composition* SEC Filings
* Stock Information
*
BACK
* Stock Information
* Stock Information
* Stock Quote & Chart * Historic Stock Lookup * Investment Calculator* Investor FAQs
* Contact IR
* Contact
Merrimack Pharmaceuticals MERRIMACK PHARMACEUTICALS, INC. (THE “COMPANY”) IS A BIOPHARMACEUTICAL COMPANY BASED IN CAMBRIDGE, MASSACHUSETTS THAT IS ENTITLED TO RECEIVE CONTINGENT MILESTONE PAYMENTS RELATED TO ITS SALE OF ONIVYDE® TO IPSEN S.A. (“IPSEN”) IN APRIL 2017. THE COMPANY DOES NOT HAVE ANY ONGOING RESEARCH OR DEVELOPMENT ACTIVITIES AND IS SEEKING POTENTIAL ACQUIRERS FOR ITS REMAINING PRECLINICAL AND CLINICAL ASSETS. THE COMPANY DOES NOT HAVE ANY EMPLOYEES AND INSTEAD USES EXTERNAL CONSULTANTS FOR THE OPERATION OF THE COMPANY. PARTNERING OPPORTUNITIESBack to top
One Broadway, 14th floorCambridge, MA 02142
617-720-8606
info@merrimack.com
* Privacy Policy
* Terms of Use
* Contact
2021 Merrimack.
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0